pharma news today obesity glp-1 Pipeline Update: August 2025 - Prime Therapeutics GLP-1 Agonists Weight Loss Drugs

Keep in mind that about 14% of people taking semaglutide may lose less than 5% of their body weight after 68 weeks, so for some, exploring alternatives like tirzepatide designed to target multiple hormone receptors might be necessary

8 yrsCN4.8/5.0 28% Reorder rate 971 Interested customers 1/1 Matches all High Quality Cosmetic Grade Copper Peptide GHK-Cu Powder AHK-cu Powder $7-14 Min

Headaches occur in about 10% to 15% of users, most commonly during the first two weeks

En la actualidad, estos medicamentos se han convertido en el tema del momento en el tratamiento de la obesidad

10.1038/npp.2012.112 27 OgilvyC

Focus 4: Emerging Pipeline and Portfolio Diversification (Gene Editing, etc.) Investors will watch for updates on non-GLP-1 assets, including oncology, gene therapies, and the recent up-to-$7 billion acquisition of Kelonia Therapeutics